This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, H. Articles by Smith, D. I. Search for Related Content PubMed PubMed Citation Articles by Huang, H. Articles by Smith, D. I.

Carboxypeptidase A3 (CPA3)

A Novel Gene Highly Induced by Histone Deacetylase Inhibitors during Differentiation of Prostate Epithelial Cancer Cells¹

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Foundation, Rochester, Minnesota 55905

Butyrate and its structural analogues have recently entered clinical trials as a potential drug for differentiation therapy of advanced prostate cancer. To better understand the molecular mechanism(s) involved in prostate cancer differentiation, we used mRNA differential display to identify the gene(s) induced by butyrate. We found that the androgen-independent prostate cancer cell line PC-3 undergoes terminal differentiation and apoptosis after treatment with sodium butyrate (NaBu). A novel cDNA designated carboxypeptidase A3 (CPA3), which was up-regulated in NaBu-treated PC-3 cells, was identified and characterized. This gene expresses a 2795-bp mRNA encoding a protein with an open reading frame of 421 amino acids. CPA3 has 37–63% amino acid identity with zinc CPs from different mammalian species. It also shares 27–43% amino acid similarity with zinc CPs from several nonmammalian species, including Escherichia coli, yeast, Caenorhabditis elegans, and Drosophila. The structural similarity between CPA3 and its closest homologues indicates that the putative CPA3 protein contains a 16-residue signal peptide sequence, a 95-residue NH₂-terminal activation segment, and a 310-residue CP enzyme domain. The consistent induction of CPA3 by NaBu in several prostate cancer cell lines led us to investigate the signaling pathway involved in the induction of CPA3 mRNA. Trichostatin A, a potent and specific inhibitor of histone deacetylase, also induced CPA3 mRNA expression, suggesting that CPA3 gene induction is mediated by histone hyperacetylation. We demonstrated that CPA3 induction was a downstream effect of the treatment with butyrate or trichostatin A, but that the induction of p21^WAF1/CIP1 occurred immediately after these treatments. We also demonstrated that the induction of CPA3 mRNA by NaBu was inhibited by p21^WAF1/CIP1 antisense mRNA expression, indicating that p21 transactivation is required for the induction of CPA3 by NaBu. Our data demonstrate that the histone hyperacetylation signaling pathway is activated during NaBu-mediated differentiation of PC-3 cells, and the new gene, CPA3, is involved in this pathway.

This article has been cited by other articles:

				M. B. Dail, L. A. Shack, J. E. Chambers, and S. C. Burgess Global Liver Proteomics of Rats Exposed for 5 Days to Phenobarbital Identifies Changes Associated with Cancer and with CYP Metabolism Toxicol. Sci., December 1, 2008; 106(2): 556 - 569. [Abstract] [Full Text] [PDF]

				P. J. Lyons, M. B. Callaway, and L. D. Fricker Characterization of Carboxypeptidase A6, an Extracellular Matrix Peptidase J. Biol. Chem., March 14, 2008; 283(11): 7054 - 7063. [Abstract] [Full Text] [PDF]

				E. Kalinina, R. Biswas, I. Berezniuk, A. Hermoso, F. X. Aviles, and L. D. Fricker A novel subfamily of mouse cytosolic carboxypeptidases FASEB J, March 1, 2007; 21(3): 836 - 850. [Abstract] [Full Text] [PDF]

				Q. Xia, J. Sung, W. Chowdhury, C.-l. Chen, N. Hoti, S. Shabbeer, M. Carducci, and R. Rodriguez Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo. Cancer Res., July 15, 2006; 66(14): 7237 - 7244. [Abstract] [Full Text] [PDF]

				I. Pallares, R. Bonet, R. Garcia-Castellanos, S. Ventura, F. X. Aviles, J. Vendrell, and F. X. Gomis-Ruth Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin PNAS, March 15, 2005; 102(11): 3978 - 3983. [Abstract] [Full Text] [PDF]

				L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]

				H. Huang, D. C. Muddiman, and D. J. Tindall Androgens Negatively Regulate Forkhead Transcription Factor FKHR (FOXO1) through a Proteolytic Mechanism in Prostate Cancer Cells J. Biol. Chem., April 2, 2004; 279(14): 13866 - 13877. [Abstract] [Full Text] [PDF]

				N. Takai, J. C. Desmond, T. Kumagai, D. Gui, J. W. Said, S. Whittaker, I. Miyakawa, and H. P. Koeffler Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells Clin. Cancer Res., February 1, 2004; 10(3): 1141 - 1149. [Abstract] [Full Text] [PDF]

				G. Graziani, L. Tentori, I. Portarena, M. Vergati, and P. Navarra Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells Endocrinology, July 1, 2003; 144(7): 2822 - 2828. [Abstract] [Full Text] [PDF]

				L Bentley, K Nakabayashi, D Monk, C Beechey, J Peters, Z Birjandi, F E Khayat, M Patel, M A Preece, P Stanier, et al. The imprinted region on human chromosome 7q32 extends to the carboxypeptidase A gene cluster: an imprinted candidate for Silver-Russell syndrome J. Med. Genet., April 1, 2003; 40(4): 249 - 256. [Abstract] [Full Text] [PDF]

				S. Wei, S. Segura, J. Vendrell, F. X. Aviles, E. Lanoue, R. Day, Y. Feng, and L. D. Fricker Identification and Characterization of Three Members of the Human Metallocarboxypeptidase Gene Family J. Biol. Chem., April 19, 2002; 277(17): 14954 - 14964. [Abstract] [Full Text] [PDF]

				H. Huang, J. C. Cheville, Y. Pan, P. C. Roche, L. J. Schmidt, and D. J. Tindall PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression J. Biol. Chem., October 12, 2001; 276(42): 38830 - 38836. [Abstract] [Full Text] [PDF]

				W.-G. Zhu, R. R. Lakshmanan, M. D. Beal, and G. A. Otterson DNA Methyltransferase Inhibition Enhances Apoptosis Induced by Histone Deacetylase Inhibitors Cancer Res., February 1, 2001; 61(4): 1327 - 1333. [Abstract] [Full Text]

				S. Kang, H. Xu, X. Duan, J.-J. Liu, Z. He, F. Yu, S. Zhou, X.-Q. Meng, M. Cao, and G. C. Kennedy PCD1, a Novel Gene Containing PDZ and LIM Domains, Is Overexpressed in Several Human Cancers Cancer Res., September 1, 2000; 60(18): 5296 - 5302. [Abstract] [Full Text]

				C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar, and P. S. Klein Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen J. Biol. Chem., September 21, 2001; 276(39): 36734 - 36741. [Abstract] [Full Text] [PDF]